Hormone Replacement Therapy: Complete 2026 Guide

What Is Hormone Replacement Therapy?

HRT replaces hormones that the body no longer produces in sufficient quantities. In women, this typically means estrogen and progesterone lost during perimenopause and menopause. In men, it means testosterone that declines with age or disease. The therapy is not a single drug. It is a class of treatments spanning many formulations, routes, and dosing strategies, and the right choice depends on the individual, not a single "best" product.

The Core Hormones

Estrogen is the primary hormone prescribed for menopausal symptoms. Conjugated equine estrogens (Premarin), 17-beta estradiol, and ethinyl estradiol are the most commonly used forms. 17-beta estradiol, the bioidentical form, is favored in most current clinical guidelines because its pharmacokinetic profile is well characterized [1].

Progesterone (or a synthetic progestin) is added for any woman with an intact uterus to prevent endometrial hyperplasia. Micronized progesterone (Prometrium) is often preferred over medroxyprogesterone acetate (MPA); the French E3N cohort study found that micronized progesterone was not associated with a significant increase in breast cancer risk over roughly a decade of follow-up, while some synthetic progestins were [2]. This is observational cohort data, not a randomized trial, so it supports a preference rather than a guarantee of safety.

Testosterone in HRT

Testosterone therapy applies to male hypogonadism and, in select cases, to female sexual dysfunction. A 2019 global consensus position statement, endorsed by multiple international menopause and sexual health societies, supports short-term testosterone for hypoactive sexual desire disorder (HSDD) in postmenopausal women once other causes have been excluded [3].

Who Should Consider HRT?

The decision to start HRT depends on symptom burden, age at onset, cardiovascular risk profile, and personal or family history. HRT is not appropriate for everyone, but for many patients it is the most effective intervention available for their symptoms.

Menopausal Women

The 2022 North American Menopause Society (NAMS) position statement describes HRT as the most effective treatment option for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause (GSM) [4]. Women younger than 60 or within 10 years of menopause onset are generally the best candidates. This "timing hypothesis" was tested in the ELITE trial (N=643), which found that estradiol started within 6 years of menopause slowed progression of carotid intima-media thickness, a marker of atherosclerosis, while estradiol started 10 or more years after menopause did not show the same effect [5].

Men With Hypogonadism

The American Urological Association (AUA) 2018 guidelines define male hypogonadism as total testosterone consistently below 300 ng/dL combined with signs or symptoms such as fatigue, reduced libido, or decreased muscle mass [6]. The Testosterone Trials (TTrials, N=790) found that 12 months of testosterone gel improved sexual function, physical activity, and mood in men aged 65 and older with confirmed low testosterone [7].

Who Should Not Use HRT

Absolute contraindications include active or recent breast cancer, active liver disease, unexplained vaginal bleeding, known thrombophilic disorders, and active cardiovascular disease such as a recent heart attack or stroke. The 2022 Endocrine Society clinical practice guideline lists these explicitly [8].

Should You Start (or Change) HRT? A Decision Framework

This hub does not replace an in-person clinical evaluation. Rather, it highlights the key facts that substantively influence what clinicians should consider as the appropriate next step.

HRT Formulations: A Complete Comparison

Choosing the right formulation weighs efficacy, safety, patient preference, and cost. No single formulation is best for every patient.

Estrogen Formulations

Oral estradiol (0.5-2 mg/day) is the most commonly prescribed form worldwide. It is inexpensive, widely available, and effective. The trade-off is that oral estrogen undergoes first-pass hepatic metabolism, which increases clotting factors, sex hormone-binding globulin (SHBG), and triglycerides [9].

Transdermal estradiol (patches delivering 25-100 mcg/day, or gels and sprays) bypasses the liver. A nested case-control analysis within a large UK primary care database found no significant increase in venous thromboembolism risk with transdermal estrogen (OR 0.96, 95% CI 0.78-1.18), while oral estrogen roughly doubled it [10]. For women with elevated VTE risk, obesity, migraine with aura, or high triglycerides, transdermal is generally the preferred route.

Vaginal estrogen (creams, rings, tablets) delivers low-dose estrogen locally for GSM symptoms, with minimal systemic absorption. The 2022 NAMS position statement notes that vaginal estrogen does not require concurrent progestogen in most cases [4].

Progesterone and Progestin Options

Micronized progesterone (100-200 mg oral, cyclical or continuous) is the most commonly recommended form for endometrial protection. The REPLENISH trial (N=1,835) found that a combination of conjugated estrogens with bazedoxifene (Duavee) also provided endometrial protection without a traditional progestin, though this combination is less widely used [11].

A levonorgestrel intrauterine system (Mirena) can provide local endometrial protection and serve as the progestogen component of HRT, reducing systemic progestin exposure.

Testosterone Formulation Comparison

The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with confirmed symptomatic testosterone deficiency, with treatment goals that include restoring secondary sex characteristics and improving sexual function, general well-being, and bone mineral density [12].

Benefits of HRT: What the Evidence Shows

Vasomotor Symptom Relief

A 2004 Cochrane review of oral estrogen, with or without progestogen, versus placebo found a large and consistent reduction in hot flash frequency (RR 0.25, 95% CI 0.22-0.28) [13]. No other pharmacotherapy matches this effect size for vasomotor symptoms specifically, though non-hormonal options exist for women who cannot or prefer not to use hormones.

Bone Protection

WHI data show estrogen therapy reduced vertebral fracture risk by approximately 34% and hip fracture risk by approximately 28% [14]. For women who cannot tolerate bisphosphonates or denosumab, HRT is a viable alternative for osteoporosis prevention, though the benefit fades within 2-5 years of stopping therapy.

Cardiovascular Considerations

The relationship between HRT and cardiovascular risk depends heavily on timing. In the WHI reanalysis by Manson and colleagues (2017), women aged 50-59 who received conjugated equine estrogens alone showed a non-significant trend toward lower coronary heart disease (HR 0.76, 95% CI 0.50-1.16) and significantly lower all-cause mortality at 18-year cumulative follow-up [15]. The authors' overall conclusion, which shaped subsequent NAMS and Endocrine Society guidance, was that the benefit-risk balance favors hormone therapy for women who start it close to menopause. That conclusion does not extend to women starting HRT more than 10 years after menopause, where the cardiovascular data are less favorable. Readers who want the exact wording of the trial's conclusions should review the source paper directly [15].

Cognitive and Mood Effects

Early initiation of estrogen, within the same critical window described above, may offer some protection against cognitive decline. The ELITE trial's cognitive sub-study showed a trend toward better verbal memory in early-initiation participants, but the data are not sufficient to recommend HRT solely for cognitive protection [5].

Risks of HRT: Quantifying the Real Numbers

Every HRT discussion should address risk in absolute, not just relative, terms.

Breast Cancer

The WHI found that combined estrogen-progestin therapy (CEE + MPA) increased breast cancer risk with a hazard ratio of 1.26 (95% CI 1.00-1.59) after a mean of 5.6 years [16]. In absolute terms, this is roughly 8 additional cases per 10,000 women per year, and the confidence interval borders on no effect at its lower bound. Estrogen-alone therapy in women with a prior hysterectomy did not increase breast cancer risk and showed a non-significant decrease (HR 0.77, 95% CI 0.59-1.01) at 13-year follow-up [17].

Venous Thromboembolism

Oral estrogen roughly doubles VTE risk, from about 1.5 to 3 per 1,000 women per year in the 50-59 age group. Transdermal estrogen has not shown the same increase in observational data [10]. This distinction is clinically actionable and is the main reason route selection matters as much as the decision to treat at all.

Stroke

The WHI reported increased stroke risk with oral conjugated equine estrogen (HR 1.37, 95% CI 1.07-1.76) [16]. The absolute risk increase was small, roughly 1 additional stroke per 1,000 women per year. Low-dose transdermal estrogen (under 50 mcg/day) has not been associated with increased stroke risk in observational studies [10].

Male TRT Risks

The TRAVERSE trial (N=5,246), published in 2023, was the first large randomized trial powered specifically for cardiovascular outcomes in men on testosterone. It found no significant increase in major adverse cardiovascular events (HR 0.99, 95% CI 0.81-1.21) over a median 33-month follow-up [18]. Elevated hematocrit (above 54%) was more common in testosterone-treated men than in the placebo group, which is why hematocrit monitoring is part of standard TRT follow-up.

How to Start HRT: A Step-by-Step Protocol

Pre-Treatment Evaluation

Before starting HRT, clinicians should obtain a complete history (cardiovascular risk, VTE history, breast cancer family history, liver disease), a physical exam including breast and pelvic exam, and baseline labs. For women, labs include FSH if menopausal status is uncertain, a lipid panel, and mammography. For men, evaluation includes two morning total testosterone levels drawn on separate days, plus LH, FSH, CBC, PSA, and a metabolic panel [6, 12].

Initiating Therapy

Start low. For menopausal women, transdermal estradiol 25-50 mcg/day or oral estradiol 0.5-1 mg/day is a reasonable starting dose. Add micronized progesterone 100-200 mg nightly if the uterus is intact. Reassess symptoms at 4-8 weeks and titrate as needed [4].

For men with confirmed hypogonadism, testosterone cypionate 100 mg IM weekly or testosterone gel 50 mg daily are common starting regimens. Check total testosterone, free testosterone, hematocrit, and PSA at 3 months [12].

Monitoring Schedule

Women on HRT: reassess at 3 months, then annually. Annual evaluation should include symptom review, blood pressure, breast exam, mammography per age-appropriate guidelines, and a discussion of ongoing benefit-risk balance [4].

Men on TRT: check testosterone trough level, CBC (hematocrit), PSA, and hepatic function at 3 months, 6 months, then every 6-12 months. The AUA recommends holding testosterone if hematocrit exceeds 54% and considering therapeutic phlebotomy if symptomatic [6].

Bioidentical vs. Synthetic vs. Compounded: Clearing Up the Confusion

Defining Terms

"Bioidentical" means the hormone molecule is chemically identical to what the human body produces. FDA-approved bioidentical options include 17-beta estradiol (oral, patch, gel) and micronized progesterone. "Synthetic" refers to molecules not found in the human body, such as medroxyprogesterone acetate (MPA) or ethinyl estradiol. Both categories include FDA-approved medications with standardized dosing.

Compounded Hormones

Compounded bioidentical hormone therapy (cBHT) is prepared by compounding pharmacies in custom doses or combinations. A 2020 National Academies of Sciences, Engineering, and Medicine (NASEM) report concluded that the evidence for cBHT's safety and efficacy compared with FDA-approved HRT is insufficient, and it raised concerns about inconsistent potency and contamination [19]. The Endocrine Society, NAMS, and ACOG recommend FDA-approved formulations over compounded alternatives when an FDA-approved option is available [8].

Compounded products may still be appropriate when a patient needs a dose or combination that is not commercially available. When compounding is necessary, sourcing from an FDA-registered 503B outsourcing facility rather than a traditional 503A pharmacy is generally preferred.

Duration of Therapy: When to Stop

There is no universal time limit. The 2022 NAMS position statement recommends individualized duration based on ongoing symptom burden and risk reassessment rather than an arbitrary cutoff [4]. Many women experience symptom return upon stopping, and some continue therapy well into their 60s or beyond.

Tapering Strategies

Gradual dose reduction over 3-6 months may reduce rebound symptoms compared with abrupt cessation, though the evidence for this specific approach is limited. Some clinicians reduce the estrogen dose by 50% for 3 months, then discontinue. Others switch from systemic to vaginal-only estrogen if GSM symptoms persist.

For men on TRT, abrupt discontinuation suppresses the hypothalamic-pituitary-gonadal axis. A supervised taper with optional short-course clomiphene or hCG may help preserve endogenous production, particularly in younger men [6].

Special Populations

Premature Ovarian Insufficiency

Women with primary ovarian insufficiency (POI, menopause before age 40) should generally receive HRT at least until the average age of natural menopause (51 years) to reduce cardiovascular, bone, and cognitive risks associated with prolonged estrogen deficiency. A 2016 ESHRE guideline recommends physiologic-dose estradiol plus progesterone rather than oral contraceptive pills for this population [20].

Transgender Hormone Therapy

Gender-affirming hormone therapy (GAHT) follows distinct protocols. The Endocrine Society's 2017 guideline recommends estradiol (oral, transdermal, or IM) plus an anti-androgen for transfeminine patients, and testosterone (IM or transdermal) for transmasculine patients. Monitoring includes estradiol or testosterone levels, lipid panel, liver function, and CBC at 3 months, then every 6-12 months [21].

Perimenopause

Women in perimenopause with bothersome VMS may benefit from low-dose oral contraceptives (if under 50, non-smoking, with no cardiovascular contraindications) or low-dose HRT. The transition to standard HRT typically occurs around age 50-51, guided by FSH levels and symptom pattern.

Cost and Access in 2026

Generic oral estradiol costs roughly $10-25/month at most pharmacies. Transdermal patches (generic estradiol) run about $30-80/month. Brand-name gels and sprays cost $150-350/month without insurance. Micronized progesterone (generic Prometrium) runs $15-40/month. Generic testosterone cypionate costs about $30-60/month for men.

Most commercial insurance plans and Medicare Part D cover FDA-approved HRT formulations. Prior authorization may be required for brand-name products or higher doses. Compounded hormones are typically not covered by insurance and cost $50-200/month out of pocket.

Patients seeking telehealth-based HRT can access board-certified providers through platforms like HealthRX.com, which offers lab-inclusive treatment plans, prescription management, and ongoing monitoring with licensed physicians in all 50 states.